Nieschlag E, Behre HM (2010) Approaches to hormonal male contraception. In: E Nieschlag, HM Behre, S Nieschlag (eds) Andrology: Male reproductive health and dysfunction. 3rd ed. Springer, Heidelberg, pp 577–588
Chapter
Google Scholar
Srinath BR, Wickings EJ, Witting C, Nieschlag E (1983) Active immunization with follicle-stimulating hormone for fertility control: a four 1/2 year study in male rhesus monkeys. Fertil Steril 40:110–117
PubMed
CAS
Google Scholar
Mauss J, Börsch G, Richter E, Bormacher K (1974) Investigations on the use of testosterone oenanthate as a male contraceptive agent. Contraception 19:281–289
Article
Google Scholar
World Health Organization Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955–959
Article
Google Scholar
World Health Organization Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligospermia in normal men. Fertil Steril 65:821–829
Google Scholar
Waites GM (2003) Development of methods of male contraception: impact of the World Health Organization Task Force. Fertil Steril 80:1–15
Article
PubMed
Google Scholar
Behre HM, Nieschlag E (2012) Testosterone preparations for clinical use in males. In: Testosterone: Action. Deficiency, substitution (ed. E Nieschlag, HM Behre). 4th ed. Cambridge University, Cambridge, pp 309–335
Chapter
Google Scholar
Behre HM, Baus S, Kliesch S, et al (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocr Metab 80:2394–2403
PubMed
CAS
Google Scholar
McLachlan RI, McDonald J, Rushford D, et al (2000) Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male contraception. Contraception 62:73–78
Article
PubMed
CAS
Google Scholar
Nieschlag E, Hoogen H, Bölk M, et al (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception 18:607–614
Article
PubMed
CAS
Google Scholar
Nieschlag E (2006) Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol 65:275–281
Article
CAS
Google Scholar
Zhang GY, Gu YQ, Wang XH, et al (1999) A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 84:3642–3647
PubMed
CAS
Google Scholar
Gu YQ, Wang XH, Xu D, et al (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562–568
Article
PubMed
CAS
Google Scholar
Gu Y, Liang X, Wu W, et al (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 94:1910–1915
Article
PubMed
CAS
Google Scholar
Zhang L, Shal IH, Liu Y, et al (2006) The acceptability of an injectable, once-a-month male contraceptive in China. Contraception 73:548–553
Article
PubMed
Google Scholar
Kamischke A, Plöger D, Venherm S, et al (2000) Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol 53:43–52
Article
CAS
Google Scholar
Qoubaitary A, Meriggiola C, Ng CM, et al (2006) Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl 27:853–867
Article
PubMed
CAS
Google Scholar
Nieschlag E, Vorona E, Wenk M, et al (2011) Hormonal male contraception in men with normal and subnormal semen parameters. Int J Androl 34:556–567
Article
PubMed
CAS
Google Scholar
Knuth UA, Behre H, Belkien L, et al (1985) Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril 44:814–821
PubMed
CAS
Google Scholar
von Eckardstein S, Noe G, Brache V, et al (2003) International Committee for Contraception Research, The Population Council. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 88:5232–5239
Article
Google Scholar
Liu PY, Swerdloff RS, Anawalt BD, et al (2008) Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 93:1774–1783
Article
PubMed
CAS
Google Scholar
Büchter D, von Eckardstein S, von Eckardstein A, et al (1999) Clinical trials of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 84:1244–1249
PubMed
Google Scholar
Soufir JC, Meduri G, Ziyyat A (2011) Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod 26:1708–1714
Article
PubMed
CAS
Google Scholar
Nieschlag E (2011) The struggle for male hormonal contraception. Best Pract Res Clin Endocrinol Metab 25:369–375
Article
PubMed
CAS
Google Scholar